Sanofi-Synthelabo and Pfizer conclude an agreement on the divestment of Campto® (irinotecan) conditional upon completi
Sanofi-Synthelabo and Pfizer conclude an agreement on the divestment of Campto® (irinotecan) conditional upon completion of Sanofi-Synthelabo's offer for Aventis Paris, June 25, 2004 Sanofi-Synthélabo announced today that it has signed an agreement with Pfizer Inc. regarding the divestment of Aventis' interests in Campto® (irinotecan) in response to requests made by the competition authorities. Subject to the consent of the US Federal Trade Commission and the success of Sanofi-Synthelabo's offer for Aventis, Pfizer will take over key clinical studies for Campto® that are currently conducted